Department of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
J Ovarian Res. 2022 May 14;15(1):61. doi: 10.1186/s13048-022-00987-1.
Emerging evidence identifies enhancer RNAs (eRNAs) as a class of regulatory ncRNAs that can contribute to the transcription of target genes. In this study, we used an integrated data analysis method to identify the important role of eRNAs in ovarian cancer (OC).
Gene expression profiles and clinical information from The Cancer Genome Atlas (TCGA) database were used for this study. Based on expression analysis using GEPIA2 gene and Kaplan-Meier survival was performed to ensure the significance of the selected enhancer RNA ADCY10P1 in OC. Next, we explored the correlation and clinical significance between ADCY10P1 and target gene NFYA. Furthermore, we evaluated the effects of overexpression of ADCY10P1 on the proliferation, migration, invasion and epithelial-mesenchymal transformation (EMT) of OC cell lines. We also investigated the biological function enrichment score of ADCY10P1 and verified it with OC cell lines. Finally, external validation was conducted, and the prognostic value of the ADCY10P1 in different tumors was demonstrated.
We selected the eRNA ADCY10P1 associated with OC prognosis, with NFYA as its predicted target gene. Low ADCY10P1 expression was found to be associated with poor overall survival, high histological grade, and advanced stage of OC. Additionally, overexpression of ADCY10P1 inhibited the proliferation, migration, invasion and EMT phenotype of OC cell lines. Furthermore, ADCY10P1 was observed to inhibit glycolysis and fatty acid metabolism, thereby affecting OC progression. Meanwhile, OC tissue samples were externally validated. In addition, the pan-cancer analysis revealed that ADCY10P1 had prognostic value in other cancers.
This study showed that ADCY10P1 plays a key role in OC progression and may facilitate prognosis prediction.
新出现的证据表明，增强子 RNA（eRNA）是一类调节 ncRNA，可促进靶基因的转录。在这项研究中，我们使用综合数据分析方法来确定 eRNA 在卵巢癌（OC）中的重要作用。
本研究使用了来自癌症基因组图谱（TCGA）数据库的基因表达谱和临床信息。基于 GEPIA2 基因表达分析和 Kaplan-Meier 生存分析，以确保选择的增强子 RNA ADCY10P1 在 OC 中的重要性。接下来，我们探索了 ADCY10P1 与靶基因 NFYA 之间的相关性和临床意义。此外，我们评估了过表达 ADCY10P1 对 OC 细胞系增殖、迁移、侵袭和上皮-间充质转化（EMT）的影响。我们还评估了 ADCY10P1 的生物学功能富集评分，并通过 OC 细胞系进行了验证。最后，进行了外部验证，并展示了 ADCY10P1 在不同肿瘤中的预后价值。
我们选择了与 OC 预后相关的 eRNA ADCY10P1，其预测的靶基因是 NFYA。低表达 ADCY10P1 与 OC 患者总生存期差、组织学分级高和疾病分期晚有关。此外，过表达 ADCY10P1 抑制 OC 细胞系的增殖、迁移、侵袭和 EMT 表型。此外，观察到 ADCY10P1 抑制糖酵解和脂肪酸代谢，从而影响 OC 的进展。同时，对 OC 组织样本进行了外部验证。此外，泛癌分析表明 ADCY10P1 在其他癌症中具有预后价值。
本研究表明，ADCY10P1 在 OC 进展中起关键作用，并可能有助于预后预测。
